Skip to main content

Table 1 Clinical and treatment characteristics for maximum involvement of biopsy core (MIBC) stratified by quartile

From: The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer

Variable MIBC by quartile
  1st(<10%) 2nd(<30%) 3rd(<70%) 4th(≥70%) p
Patients (n) 144 135 147 164  
Age (y), median (IQR) 68 (62–73) 69 (63–74) 69 (62–74) 71 (64–75) 0.48*
PSA (ng/mL), median (IQR) 7.6 (5.3-10.6) 7.2 (4.9-10.4) 7.5 (5.0-12.2) 10.4 (6.7-20.4) <0.001*
 <10 70% 73% 65% 48% <0.0001
 10-20 23% 17% 25% 27%  
 ≥20 7% 10% 10% 26%  
T-stage      <0.0001
 T1-T2a 91% 92% 79% 59%  
 T2b-T2c 6% 4% 17% 26%  
 T3-T4 3% 4% 4% 15%  
Gleason score      <0.0001
 2-6 67% 54% 22% 8%  
 7 26% 39% 60% 49%  
 8 5% 6% 10% 17%  
 9-10 2% 1% 8% 26%  
Percent cores positive 17% (13-33%) 25% (17-40%) 41% (25-58%) 63% (46-83%) <0.001*
Percent cancer volume 0.8% (0.5-1.7%) 2.9% (1.9-5.0%) 11.7% (6.7-18.8%) 33.6% (20.8-48.9%) <0.001*
NCCN risk group      <0.0001
 Low 52% 37% 14% 5%  
 Intermediate 35% 45% 59% 39%  
 High 13% 18% 27% 56%  
RT dose (Gy), median (IQR) 77 (76–78) 77 (76–78) 77 (77–78) 78 (77–78) <0.001*
Pelvic RT 12% 17% 25% 55% <0.0001
ADT use 29% 31% 35% 66% <0.0001
ADT duration, median (IQR) 6.9 (6.0-18.7) 6.1 (4.0-18.7) 6.4 (6.0-24.4) 20.9 (6.3-25.6) 0.2*
  1. Abbreviations: IQR = inter-quartile range; PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer Network; RT = radiotherapy; ADT = androgen deprivation therapy.
  2. *Analysis of variance.
  3. Chi-square test.